Table 1.

Population characteristics at baseline

VariablesCyclophosphamide-Treated Patients (n=127)Patients Not Treated with Cyclophosphamide (n=145)P Value
At baseline (the time of biopsy)
 Men (n)101 (80%)89 (61%)0.001
 Body mass index (kg/m2)26.6±3.627.1±5.00.40
 Age (yr)53±1349±150.05
 Year of biopsy2001±72002±60.10
 Follow-up duration (yr)7.0 (4.0–11.4)5.4 (3.0–8.4)0.26
 Positive family history for malignancya12/82 (15%)12/98 (12%)0.64
 Current/former smokera56/94 (60%)55/107 (51%)0.24
 eGFR-MDRD4 (ml/min per 1.73 m2)60±2475±22<0.001
 Serum creatinine (mg/dl)1.2 (1.0–1.6)1.0 (0.8–1.1)<0.001
 Serum albumin (g/dl)2.2±0.682.7±0.63<0.001
 Nephrotic syndrome at presentation121 (95%)119 (82%)0.001
 Protein to creatinine ratio (g/g)8.9 (5.7–11.1)4.6 (3.0–7.6)<0.001
 ACEi/ARB use112 (88%)134 (92%)0.24
 Statin use81 (64%)87 (60%)0.52
 Other BP-lowering medication39 (31%)22 (15%)0.002
Therapy
 Interval from baseline to start of therapy (mo)12 (5–26)
 Serum creatinine at start of therapy (mg/dl)1.6 (1.2–2.0)
 Prior immunosuppressive therapy27 (21%)22 (15%)0.19
 Cumulative cyclophosphamide dose (g)37 (21–46)n/a
Outcomes
 Death17 (13%)7 (5%)0.01
 Malignancies16 (13%)4 (3%)0.002
  • Data are presented as mean±SD, median (interquartile range), or percentage where appropriate. eGFR-MDRD4, eGFR calculated with the abbreviated Modification of Diet in Renal Disease equation for mass spectrometry-standardized creatinine; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; n/a, not applicable.

  • a The denominator differs from the total number of patients because of missing data for this variable.